120 years and still making history

Headquartered in Hungary and founded in 1901, Gedeon Richter Plc. is an innovation-driven specialty pharmaceutical company

About

Think global act local

Wherever we operate, environmental protection and sustainable development of the economic and social environment are paramount

Local Responsibility

Experts in female and bone health

We are leading the way in key aspects of female and bone health

Our Expertise

Latest news

One of our products awarded Medicine of the Year prize

News

120 years and still making history

Headquartered in Hungary and founded in 1901, Gedeon Richter Plc. is an innovation-driven specialty pharmaceutical company

The pharmacist Gedeon Richter received approval to manufacture medicines.

Mr. Richter bought a 3,252 m2 area in Budapest and set up the first production facility.

The company was converted into a stock corporation, but the majority of the shares and management remained with the Richter family.

The first foreign branch was opened in Zagreb in the same year.

Ten branches were founded abroad.

With the beginning of the planned economy era, the company was nationalized.

The company's first own oral contraceptive was launched.

In the course of privatization, the state-owned company was converted into a joint stock company.

The registered shares were listed on the Budapest Stock Exchange. This gradually led to a reduction in state participation, which today is just 25%.

The hormone production plant, built according to the most modern standards, went into operation.

The biotechnological test facility was officially opened.

Gedeon Richter bought the Swiss pharmaceutical research company PregLem and the contraceptive portfolio from the German company Grünenthal.

Debrecen biotechnology plant.

LATAM expansion.

Biosimilar osteoporosis medicine.

Think global act local

Wherever we operate, environmental protection and sustainable development of the economic and social environment are paramount.

Gedeon Richter is represented on five continents. It has direct presence in 50 countries through 8 manufacturing units, 19 representative offices and 41 commercial and marketing companies, and its products are available in more than 100 countries in Europe, the United States, the CIS member states, Japan and the Middle East.

Gedeon Richter (Switzerland) AG was founded in 2011 and represents the international pharmaceutical company Gedeon Richter in Switzerland as a wholly owned subsidiary. Thanks to the company’s own marketing and sales network, customers now have direct contact with Gedeon Richter in the area of gynecology. Since 2011, the company has been expanding its marketing and sales network in Western European countries in the gynecology division. Gedeon Richter combines innovative and high-quality cutting-edge technology with the long Hungarian tradition of pharmaceutical production. The focus is on the commitment to social responsibility.

It is our goal to become a long-term and valuable partner of doctors and women with high-quality products and reliable services. We believe that good communication and cooperation will be critical to us achieving this partnership and our aim is always to continue contributing to the qualitative improvement of human life in the future.

Transparency gedeonrichter.com

Experts in female and bone health

We are leading the way in key aspects of female and bone health.

Gynecology

  • Belarina®
  • Belara®
  • Desoren20®
  • Desoren30®
  • Azalia®
  • Levosert®
  • Estinette20®
  • Estinette30®

Osteology

  • Terrosa®

You can find specialist and patient information at www.swissmedicinfo.ch.

Innovation beyond female health

Gedeon Richter manufactures more than 200 drugs, and its products include original, generic, biosimilar and licensed products which provide modern and reasonably priced treatments in almost every therapeutic area. The company focuses on developing and manufacturing central nervous system, cardiovascular and gynaecological products.

Innovation and the research of original drug molecules have been key elements in the Company’s strategy since its foundation in 1901. With more than 1,200 employees in the field of research and development Richter today is the most significant pharmaceutical research base in the Central and Eastern European region. The Richter Group spent EUR 154 million on research and development in 2020, which amounts to 9.5 per cent of its consolidated sales revenue. Drug research and development entails four strategic directions: recombinant biotechnological activities, research and development of new chemical entities (focusing on central nervous system), late stage women’s healthcare projects and generic products.

Latest news